First-year quality of life assessment of an intra-arterial (RADPLAT) versus intravenous chemoradiation phase III trial
| Autor: | Frans J. M. Hilgers, Alfons J. M. Balm, R. Theo Gregor, Coen R.N. Rasch, A. H. Ackerstaff, R Kröger, Ruud Wiggenraad, D. Rietveld, Jan de Boer |
|---|---|
| Přispěvatelé: | Ear, Nose and Throat, Other departments, Radiation Oncology |
| Jazyk: | angličtina |
| Rok vydání: | 2009 |
| Předmět: |
Male
medicine.medical_specialty Alcohol Drinking Nausea Vomiting Health Behavior Antineoplastic Agents Xerostomia law.invention Randomized controlled trial Quality of life law Surveys and Questionnaires medicine Health Status Indicators Humans Infusions Intra-Arterial Infusions Intravenous Fatigue Mouth neoplasm Hypopharyngeal Neoplasms business.industry Head and neck cancer Smoking Middle Aged medicine.disease Combined Modality Therapy Surgery Clinical trial Oropharyngeal Neoplasms Otorhinolaryngology Head and Neck Neoplasms Multivariate Analysis Quality of Life Female Mouth Neoplasms medicine.symptom Cisplatin business Chemoradiotherapy |
| Zdroj: | Ackerstaff, A H, Balm, A J M, Rasch, C R N, De Boer, J P, Wiggenraad, R, Rietveld, D H F, Gregor, R T, Kröger, R & Hilgers, F J M 2009, ' First-year quality of life assessment of an intraarterial (radplat) versus intravenous chemoradiation phase III trial ', Head and Neck, vol. 31, no. 1, pp. 77-84 . https://doi.org/10.1002/hed.20937 Head & neck, 31(1), 77-84. John Wiley and Sons Inc. Head and Neck, 31(1), 77-84. Wiley Subscription Services, Inc., A Wiley Company Hoboken |
| ISSN: | 1043-3074 |
| Popis: | Background. We report the results of a multicenter randomized phase III study, assessing quality of life (QOL) in intra-arterial (IA) versus standard intravenous (IV) chemoradiation in advanced head and neck cancer. Methods. Two hundred seven patients with inoperable stage IV disease—152 men and 55 women; mean age, 55 years—were included in this study. The patients were treated with standard radiotherapy with 4 weekly IA or 3 weekly IV cisplatin infusions. The QOL assessments carried out were EORTC-C30, H&N35, and trial-specific questionnaires. Results. Overall QOL deteriorated in all patients during treatment, is gradually improving over 1 year. IA patients showed significantly less nausea and vomiting at week 7 (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text